LigaChem Biosciences Inc
LigaChem Biosciences Inc is a biotechnology company that develops and commercializes pharmaceutical products and medical research tools, primarily generating revenue through product sales and research collaborations.
Business. LigaChem Biosciences Inc is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily listed on the KOSDAQ under the ticker symbol 141080.KQ. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.
Analyst recommendations
9 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
LigaChem Biosciences Inc is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily listed on the KOSDAQ under the ticker symbol 141080.KQ. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.
LigaChem Biosciences Inc has a strong liquidity position, with a current ratio of 8.54, indicating that the company holds significantly more current assets than current liabilities. The company maintains a low debt-to-equity ratio of 0.01, suggesting minimal reliance on debt financing and a strong equity base. However, the company's operating cash flow is negative at -124.53 billion KRW, and free cash flow is also negative at -90.98 billion KRW, indicating that the company is currently not generating sufficient cash from operations to fund its activities.
The company's profitability metrics are weak, with a return on equity of -14.63% and a return on assets of -10.58%, both significantly below the industry median for biotechnology and medical research firms. These negative returns suggest that the company is not effectively utilizing its equity or assets to generate profits. The operating income is negative at -106.53 billion KRW, and the net income is also negative at -74.28 billion KRW, further highlighting the company's unprofitable operations.
LigaChem Biosciences Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. The company's revenue is entirely derived from its core pharmaceutical and medical research activities, with no significant diversification into other product lines or geographic regions.
The company's growth trajectory is uncertain, with no clear revenue growth reported in the most recent financial period. The company's capital expenditures are relatively low at -6.04 billion KRW, suggesting limited investment in new projects or expansion. Analysts have provided a mean price target of 197,500 KRW and a median price target of 205,000 KRW, with a mean recommendation of 1.78, indicating a generally positive outlook from analysts.
The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and strong equity base reduce the likelihood of financial distress. However, the company's negative operating and free cash flows suggest potential liquidity challenges in the future. The risk assessment indicates that the company is not currently facing significant dilution pressure, with a low dilution risk rating.
Recent events related to LigaChem Biosciences Inc include the publication of its latest financial results, which show continued unprofitability and negative cash flows. The company has not disclosed any major new product launches or strategic partnerships in the most recent filings. Analysts have provided a range of price targets, with the highest at 250,000 KRW and the lowest at 150,000 KRW, indicating a wide range of expectations for the company's future performance.
- LigaChem Biosciences Inc has a strong liquidity position with a current ratio of 8.54 and a low debt-to-equity ratio of 0.01.
- The company is currently unprofitable, with a return on equity of -14.63% and a return on assets of -10.58%.
- Revenue is concentrated in a single business segment, with no significant geographic diversification.
- Analysts have provided a generally positive outlook, with a mean price target of 197,500 KRW and a median price target of 205,000 KRW.
- The company faces potential liquidity challenges due to negative operating and free cash flows.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1 061,08 |
| Revenue | —no estimate | —no estimate | 234,1B KRW |
| Operating income | —no estimate | —no estimate | -4,6B KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- LigaChem Biosciences Inc Market data — financials · 2026-05-26
- LigaChem Biosciences Inc Market data — analyst estimates · 2026-05-26